The University of Kansas Heartland Institute for Clinical and Translational Research (HICTR) was established in 2007 in response to the national CTSA initiative. The vision of the HICTR is to improve the health of Kansans by creating a novel and transformative translational research enterprise from bench to bedside to community. Particular strengths of our HICTR program are an entrepreneurial drug and device discovery and development program and a well-developed and highly accomplished community-based research program.
The specific aims of the HICTR are to: 1) create a new academic home with innovative training programs for clinical and translational Investigators;2) provide an enhanced coordinated translational research infrastructure;and 3) actively engage the community in developing, testing, and disseminating research, by capitalizing on and expanding existing networks, to improve the health of all Kansans?especially those in rural, underserved and other target communities. The proposed infrastructure and educational programs of the HICTR will address the challenges facing clinical and translational investigators by enhancing and integrating existing resources for easier access, developing new innovative resources, and capitalizing on resources residing in research centers across the university?including our KINBRE and five COBRE grants~and our HICTR network institutions. In support of our aims, we have marshaled an impressive array of institutional, corporate, and community resources in planning, developing, and establishing the HICTR. The HICTR will provide new infrastructure and training and educational programs to support investigators'clinical and translational research?taking laboratory discoveries to first trials in humans (Tl research) and moving research through to studies on dissemination and implementation of research findings to practice (T2 research). With extraordinary institutional and community support, we already have made tremendous progress. Funding from the CTSA program will allow the University of Kansas'HICTR the opportunity to fully realize its potential not only for our region, but also to contribute to the national CTSA Consortium.
The University of Kansas Heartland Institute for Clinical and Translational Research is an academic home for clinical and translational research, providing support to scientists and involving the community, so that discoveries and research findings wi|l be brought more rapidly to the point of care, thus improving the health of all Kansans.
|Nollen, Nicole L; Cox, Lisa Sanderson; Mayo, Matthew S et al. (2018) A randomized clinical trial of counseling and nicotine replacement therapy for treatment of African American non-daily smokers: Design, accrual, and baseline characteristics. Contemp Clin Trials 70:72-82|
|Chen, Weiqi; Hu, Yong; Zhang, Xiangzhou et al. (2018) Causal risk factor discovery for severe acute kidney injury using electronic health records. BMC Med Inform Decis Mak 18:13|
|Naddaf, Elie; Barohn, Richard J; Dimachkie, Mazen M (2018) Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics 15:995-1005|
|Mansour, Zaid M; Martin, Laura E; Lepping, Rebecca J et al. (2018) Brain Response to Non-Painful Mechanical Stimulus to Lumbar Spine. Brain Sci 8:|
|Gibbs, Heather D; Ellerbeck, Edward F; Gajewski, Byron et al. (2018) The Nutrition Literacy Assessment Instrument is a Valid and Reliable Measure of Nutrition Literacy in Adults with Chronic Disease. J Nutr Educ Behav 50:247-257.e1|
|Atay, Safinur; Wilkey, Daniel W; Milhem, Mohammed et al. (2018) Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers. Mol Cell Proteomics 17:495-515|
|Choi, In-Young; Lee, Phil; Adany, Peter et al. (2018) In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis. Mult Scler 24:1029-1038|
|Pfeifer, Emily; Parrott, Jessica; Lee, Gene T et al. (2018) Regulation of human placental drug transporters in HCV infection and their influence on direct acting antiviral medications. Placenta 69:32-39|
|Kimminau, Kim S; Jernigan, Cheryl; LeMaster, Joseph et al. (2018) Patient vs. Community Engagement: Emerging Issues. Med Care 56 Suppl 10 Sup:S53-S57|
|Bridges, Kristina M; Diaz, Francisco J; Wang, Zhiwen et al. (2018) Relating Stool Microbial Metabolite Levels, Inflammatory Markers and Dietary Behaviors to Screening Colonoscopy Findings in a Racially/Ethnically Diverse Patient Population. Genes (Basel) 9:|
Showing the most recent 10 out of 280 publications